
Lundbeck’s superagonist prompts 61.2% seizure reduction
Lundbeck’s receptor superagonist designed to treat seizures associated with developmental and epileptic encephalopathies (DEEs) has seen a 61.2% reduction in total seizures in a Phase Ib/IIa trial. Interim analysis from the open-label extension (OLE) …